PSTX News and Press, Poseida Therapeutics Inc. From 07/26/21

Poseida Therapeutics (PSTX) announces the appointment of biotechnology industry veteran Cynthia Collins to the company's board of directors.Collins most recently served as the CEO of Editas Medicine, and prior to that served as the CEO of Human Longevity. For further details ...

Poseida Therapeutics Appoints Cynthia Collins to Board of Directors PR Newswire SAN DIEGO , July 26, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform...

Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders PR Newswire SAN DIEGO , June 2, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platfor...

“We are bullish on the cell and gene therapy space,” noted BTIG analyst Justin Zelin highlighting the importance of stock picking in the area given “the limited targets and indications to market.”In the area of cell therapy, Zelin initiates the coverage on six comp...

The following slide deck was published by Poseida Therapeutics, Inc. in conjunction with this event. For further details see: Poseida Therapeutics (PSDX) Presents At Bank of America Merill Lynch Virtual Healthcare Conference

Poseida Therapeutics (PSTX): Q1 GAAP EPS of -$0.62 beats by $0.05.Cash, cash equivalents and short-term investments of $270M.Press Release For further details see: Poseida Therapeutics EPS beats by $0.05

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 PR Newswire SAN DIEGO , May 11, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic ...

Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting Preclinical data demonstrates potential of piggyBac® DNA delivery system in developing gene the...

Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board PR Newswire SAN DIEGO , May 6, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genet...

Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference PR Newswire SAN DIEGO , May 5, 2021 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engi...